Reacción medicamentosa adversa                                               Adverse drug reaction  

Johnson MP. Transitions of care in patients receiving oral anticoagulants: general principles, procedures, and impact of new oral anticoagulants. J Cardiovasc Nurs. 2013; 28(1):54-65. doi: 10.1097/JCN.0b013e31823776e6.

Ahn HJ, Park HA. Adverse-drug-event surveillance using narrative nursing records in electronic nursing records. Comput Inform Nurs. 2013; 31(1):45-51. doi: 10.1097/NXN.0b013e318270106e.

Gerhart D, O'Shea K, Muller S. Advancing medication infusion safety through the clinical integration of technology. Hosp Pract (1995). 2013; 41(4):7-14.

Bourdeanu L, Luu T. Nursing perspectives on trastuzumab emtansine for the treatment of metastatic breast cancer. Clin J Oncol Nurs. 2013; 17(5):E58-62. doi: 10.1188/13.CJON.E58-E62.

Fleming S, Brady AM, Malone AM. An evaluation of the drug calculation skills of registered nurses. Nurse Educ Pract. 2013 Jul 4. doi:pii: S1471-5953(13)00121-2. 10.1016/j.nepr.2013.06.002.

Fineberg SJ, Nandyala SV, Marquez-Lara A, Oglesby M, Patel AA, Singh K. Incidence and risk factors for postoperative delirium after lumbar spine surgery. Spine (Phila Pa 1976). 2013; 38(20):1790-6. doi: 10.1097/BRS.0b013e3182a0d507.

Yeh ML. Drug safeguards to ensure the ambulatory medication safety of elderly people. Hu Li Za Zhi. 2013; 60(2):24-31. doi: 10.6224/JN.60.2.24.

Corominas H, Sánchez-Eslava L, García G, Padró I, Aimarich C, Gonzàlez J, et al. Safety profile of biological intravenous therapy in a rheumatoid arthritis patients cohort. Clinical nursing monitoring (Sebiol study). Reumatol Clin. 2013; 9(2):80-4. doi: 10.1016/j.reuma.2012.06.001.

Vogelsmeier A, Pepper GA, Oderda L, Weir C. Medication reconciliation: A qualitative analysis of clinicians' perceptions. Res Social Adm Pharm. 2013; 9(4):419-30.

Declercq T, Petrovic M, Azermai M, Vander Stichele R, De Sutter AI, et al. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2013 Mar 28;3:CD007726. doi: 10.1002/14651858.CD007726.pub2.

Alldred DP, Raynor DK, Hughes C, Barber N, Chen TF, Spoor P. Interventions to  optimise prescribing for older people in care homes. Cochrane Database Syst Rev. 2013 Feb 28;2:CD009095. doi: 10.1002/14651858.CD009095.pub2.

Murray C, Wereley A, Nixon S, Hua-Yung C, von Riedemann S, Kurtin S; Canadian Nurses Working Group on Azacitidine in MDS. Counselling and adverse event management for patients with myelodysplastic syndromes undergoing azacitidine

therapy: a practice standard for Canadian nurses. Can Oncol Nurs J. 2012; 22(4):222-34.

McLain K, Edlund BJ. Statin drugs: reducing cardiovascular risk in older adults. J Gerontol Nurs. 2012; 38(10):9-13.

Robinson S, Howie-Esquivel J, Vlahov D. Readmission risk factors after hospital discharge among the elderly. Popul Health Manag. 2012; 15(6):338-51.

Anghelescu DL, Faughnan LG, Oakes LL, Windsor KB, Pei D, Burgoyne LL. Parent-controlled PCA for pain management in pediatric oncology: is it safe? J Pediatr Hematol Oncol. 2012; 34(6):416-20.

Doyle-Lindrud S. Managing side effects of the novel taxane cabazitaxel in castrate-resistant prostate cancer. Clin J Oncol Nurs. 2012; 16(3):286-91.

Jones H. Systemic antibiotic treatment of skin, skin structure, and soft tissue infections in the outpatient setting. Adv Skin Wound Care. 2012; 25(3):132-40.

van Valen R, van Vuuren H, van Domburg RT, van der Woerd D, Hofland J, Bogers AJ. Pain management after cardiac surgery: experience with a nurse-driven pain protocol. Eur J Cardiovasc Nurs. 2012; 11(1):62-9.

 

Reacción a la perfusión                                                         Infusion reaction  

Rubin KM. Managing immune-related adverse events to ipilimumab. Clin J Oncol Nurs. 2012; 16(2):E69-75.

Hicks RW, Hernandez J. Perioperative pharmacology: a focus on vancomycin. AORN J. 2011; 93(5):593-6

Magro F, Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs. 2010; 24 Suppl 1:3-14. 

Burton BK, Guffon N, Roberts J, van der Ploeg AT, Jones SA; HOS investigators. Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II - data from the Hunter Outcome Survey. Mol Genet Metab. 2010; 101(2-3):123-9. 

Ouwerkerk J, Boers-Doets C. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. Eur J Oncol Nurs. 2010; 14(4):337-49.

Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs. 2010;14(2):E10-21. 

Namey M, Halper J, O'leary S, Beavin J, Bishop C. Best practices in multiple  sclerosis: infusion reactions versus hypersensitivity associated with biologic therapies. J Infus Nurs. 2010; 33(2):98-111. 

Viale PH. Management of hypersensitivity reactions: a nursing perspective. Oncology (W.P.). 2009; 23(2 Suppl 1):26-30. 

Kirmse J. The nurse's role in administration of intravenous immunoglobulin therapy. Home Healthc Nurse. 2009 ; 27(2):104-11.

Bagewadi S, Roberts J, Mercer J, Jones S, Stephenson J, Wraith JE. Home treatment with Elaprase and Naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively. J Inherit Metab Dis. 2008; 31(6):733-7. 

Carney PH, Ollom CL. Infusion reactions triggered by monoclonal antibodies treating solid tumors. J Infus Nurs. 2008; 31(2):74-83. 

Colwell HH, Mathias SD, Ngo NH, Gitlin M, Lu ZJ, Knoop T. The impact of infusion reactions on oncology patients and clinicians in the inpatient and outpatient practice settings: oncology nurses' perspectives. J Infus Nurs. 2007; 30(3):153-60. 

Breslin S. Cytokine-release syndrome: overview and nursing implications. Clin J Oncol Nurs. 2007; 11(1 Suppl):37-42. 

Cox-Brinkman J, Timmermans RG, Wijburg FA, Donker WE, van de Ploeg AT, Aerts  JM, Hollak CE. Home treatment with enzyme replacement therapy for mucopolysaccharidosis type I is feasible and safe. J Inherit Metab Dis. 2007; 30(6):984. 

Ulfvarson J, Mejyr S, Bergman U. Nurses are increasingly involved in pharmacovigilance in Sweden. Pharmacoepidemiol Drug Saf. 2007; 16(5):532-7. 

Khoukaz T. Administration of anti-EGFR therapy: a practical review. Semin Oncol Nurs. 2006; 22(1 Suppl 1):20-7. 

Utley M. Effective and safe IV iron and anemia management during home hemodialysis: a dialysis facility's experience. Nephrol Nurs J. 2005; 32(6):659-65.

Bonosky K, Miller R. Hypersensitivity reactions to oxaliplatin: what nurses need to know. Clin J Oncol Nurs. 2005; 9(3):325-30. 

Huddleston R, Berkheimer C, Landis S, Houck D, Proctor A, Whiteford J. Improving patient outcomes in an ambulatory infusion setting: decreasing infusion reactions of patients receiving paclitaxel and carboplatin. J Infus Nurs. 2005; 28(3):170-2. 

Gammon DC, Lizotte MW. Safety and cost-effectiveness of paclitaxel administered as a 1-hour infusion versus a 3-hour infusion for various malignancies. J Infus Nurs. 2004; 27(4):251-3. 

 
 

Riesgo de reacción a la perfusión                                                 Risk of infusion reaction  

Symons C, Rossi O, Magerl M, Andritschke K. Practical approach to self-administration of intravenous C1-INH concentrate: a nursing perspective. Int Arch Allergy Immunol. 2013;161 Suppl 1:17-20. doi: 10.1159/000351236.

Eisenberg S. Biologic therapy. J Infus Nurs. 2012; 35(5):301-13.

Atalay H, Solak Y, Acar K, Govec N, Turk S. Safety profiles of total dose infusion of low-molecular-weight iron dextran and high-dose iron sucrose in renal patients. Hemodial Int. 2011; 15(3):374-8.

Hicks RW, Hernandez J. Perioperative pharmacology: a focus on vancomycin. AORN J. 2011; 93(5):593-6

Magro F, Portela F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. BioDrugs. 2010; 24 Suppl 1:3-14.

Burton BK, Guffon N, Roberts J, van der Ploeg AT, Jones SA; HOS investigators. Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II - data from the Hunter Outcome Survey. Mol Genet Metab. 2010; 101(2-3):123-9.

Ouwerkerk J, Boers-Doets C. Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. Eur J Oncol Nurs. 2010; 14(4):337-49.

Vogel WH. Infusion reactions: diagnosis, assessment, and management. Clin J Oncol Nurs. 2010;14(2):E10-21.

Namey M, Halper J, O'leary S, Beavin J, Bishop C. Best practices in multiple  sclerosis: infusion reactions versus hypersensitivity associated with biologic therapies. J Infus Nurs. 2010; 33(2):98-111.

Viale PH. Management of hypersensitivity reactions: a nursing perspective. Oncology (W.P.). 2009; 23(2 Suppl 1):26-30.

Kirmse J. The nurse's role in administration of intravenous immunoglobulin therapy. Home Healthc Nurse. 2009 ; 27(2):104-11.

Polyzos A, Tsavaris N, Gogas H, Souglakos J, Vambakas L, Vardakas N, et al. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience. Oncology. 2009;76(1):36-41.

Bagewadi S, Roberts J, Mercer J, Jones S, Stephenson J, Wraith JE. Home treatment with Elaprase and Naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively. J Inherit Metab Dis. 2008; 31(6):733-7.

Carney PH, Ollom CL. Infusion reactions triggered by monoclonal antibodies treating solid tumors. J Infus Nurs. 2008; 31(2):74-83.

 

Colwell HH, Mathias SD, Ngo NH, Gitlin M, Lu ZJ, Knoop T. The impact of infusion reactions on oncology patients and clinicians in the inpatient and outpatient practice settings: oncology nurses' perspectives. J Infus Nurs. 2007; 30(3):153-60

 

Reacción local a la administración                                                 Administration-site reaction  

Surendiran A, Kaku MV, Adithan C. Medication error - Inadvertent high dose intradermal cloxacillin induced skin necrosis. Indian J Pharmacol. 2012; 44(1):122-3.

Poonai N, Alawi K, Rieder M, Lynch T, Lim R. A comparison of amethocaine and liposomal lidocaine cream as a pain reliever before venipuncture in children: a randomized control trial. Pediatr Emerg Care. 2012; 28(2):104-8.

Saunders C, Caon C, Smrtka J, Shoemaker J. Factors that influence adherence and strategies to maintain adherence to injected therapies for patients with multiple sclerosis. J Neurosci Nurs. 2010; 42(5 Suppl):S10-8.

Catalá M, Gómez A, Ollo B, Gurpegui M, Talens M. Safety of hymenopteran venoms immunotherapy in a cluster schedule. A nursing perspective. An Sist Sanit Navar. 2009; 32(3):409-12.

Jolly H, Simpson K, Bishop B, Hunter H, Newell C, Denney D, Oleen-Burkey M. Impact of warm compresses on local injection-site reactions with self-administered glatiramer acetate. J Neurosci Nurs. 2008; 40(4):232-9.

Santos-Blanco F. Nursing care in fluorescein angiography. Enferm Clin. 2008; 18(3):161-5.

Pielak KL, McIntyre CC, Remple VP, Buxton JA, Skowronski DM. One arm or two? Concurrent administration of meningococcal C conjugate and hepatitis B vaccines in pre-teens. Can J Public Health. 2008; 99(1):52-6.

Proudfoot C, Gamble C. Site-specific skin reactions to amethocaine. Paediatr Nurs. 2006; 18(5):26-8.

Breen M. An evaluation of two subcutaneous infusion devices in children receiving palliative care. Paediatr Nurs. 2006; 18(4):38-40.

Rosenthal D, Murphy F, Gottschalk R, Baxter M, Lycka B, Nevin K. Using a topical anaesthetic cream to reduce pain during sharp debridement of chronic leg ulcers. J Wound Care. 2001; 10(1):503-5.

Akhavan A, Bershad S. Topical acne drugs: review of clinical properties, systemic exposure, and safety. Am J Clin Dermatol; 4(7):473-92.

Cimiotti JP, Marmur ES, Nesin M, Hamlin-Cook P, Larson EL. Adverse reactions associated with an alcohol-based hand antiseptic among nurses in a neonatal intensive care unit. Am J Infect Control. 2003; 31(1):43-8.

de La Calle Valverde A, González De Aledo Linos A. Comparation of reactogenicity of vaccine combinations with an injection volume of 0,5 and 1 ml in infants. Aten Primaria. 2001; 28(4):249-55.

Baldo V, Menegon T, Bonello C, Floreani A, Trivello R; Collaborative Group. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine. 2001; 19(25-26):3472-5.

Stafford-Fox V, Guindon KM. Cutaneous reactions associated with alpha interferon therapy. Clin J Oncol Nurs. 2000; 4(4):164-8.

 

Riesgo de reacción a la administración                                           Risk of administration-site reaction  

Avşar G, Kaşikçi M. Assessment of four different methods in subcutaneous heparin applications with regard to causing bruise and pain. Int J Nurs Pract. 2013; 19(4):402-8. doi: 10.1111/ijn.12079. 

Pourghaznein T, Azimi AV, Jafarabadi MA. The effect of injection duration and  injection site on pain and bruising of subcutaneous injection of heparin. J Clin Nurs. 2013 Jul 12. doi: 10.1111/jocn.12291. 

Cole SW, Lundquist LM. Icatibant for the treatment of hereditary angioedema. Ann Pharmacother. 2013; 47(1):49-55. doi: 10.1345/aph.1R423. 

Murray C, Wereley A, Nixon S, Hua-Yung C, von Riedemann S, Kurtin S; Canadian  Nurses Working Group on Azacitidine in MDS. Counselling and adverse event management for patients with myelodysplastic syndromes undergoing azacitidine

therapy: a practice standard for Canadian nurses. Can Oncol Nurs J. 2012; 22(4):222-34. 

Sehgal VN, Verma P, Bhattacharya SN. Pathophysiology of adverse cutaneous drug reactions--applied perceptions: Part II. Skinmed. 2012; 10(6):373-83. 

Balci Akpinar R, Celebioglu A. Effect of injection duration on bruising associated with subcutaneous heparin: a quasi-experimental within-subject design. Int J Nurs Stud. 2008; 45(6):812-7. 

Girouard N, Théorêt G. Management strategies for improving the tolerability of interferons in the treatment of multiple sclerosis. Can J Neurosci Nurs. 2008;30(4):18-25. 

Lee CS, Lee KH, Jung MH, Lee HB. Rate of influenza vaccination and its adverse reactions seen in health care personnel in a single tertiary hospital in Korea. Jpn J Infect Dis. 2008; 61(6):457-60. 

Freedman SM, Cox D, Rosebrough T. A prospective baseline versus on-treatment study assessing patient perceptions of using a smaller needle when injecting intramuscular interferon beta-1 a (Avonex). J Neurosci Nurs. 2008; 40(6):350-5. 

Moore LA, Kaufman MD, Algozzine R, Irish N, Martin M, Posey CR. Adherence to therapy: using an evidence-based protocol. Rehabil Nurs. 2007; 32(6):227-32. 

Romero-Maté A, García-Donoso C, Córdoba-Guijarro S. Efficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated review. Am J Clin Dermatol. 2007;8(3):143-55. 

Ghabouli MJ, Sabouri AH, Shoeibi N, Bajestan SN, Baradaran H. High seroprotection rate induced by intradermal administration of a recombinant hepatitis B vaccine in young healthy adults: comparison with standard intramuscular vaccination. Eur J Epidemiol. 2004;19(9):871-5. 

Comley AL, DeMeyer E, Adams N, Edwards C, Gilman LC, Good A, et al. Perception of depot antipsychotics by mental health professionals. J Psychiatr Pract. 2003; 9(3):252-60. 

Foy K, Juethner SN. Enfuvirtide (T-20): potentials and challenges. J Assoc Nurses AIDS Care. 2004; 15(6):65-71. 

Lynn J. The oncology nurse's role in educating patients on endocrine therapy for metastatic breast cancer--focus on fulvestrant. Cancer Nurs. 2002; 25Suppl 2:12S-17S. 

Stafford-Fox V, Guindon KM. Cutaneous reactions associated with alpha interferon therapy. Clin J Oncol Nurs. 2000; 4(4):164-8. 

Phillips JM. Effect of subcutaneous granulocyte colony-stimulating factor injectate volume on drug efficacy, site complications, and client comfort. Oncol Nurs Forum. 1999; 26(1):87-94.

 

Versión para imprimir Versión para imprimir | Mapa del sitio
© NAAXPOT SLU © ATIC